Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | F12 | P00748 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743862 | 1.00 | TRPV1 (0.52) | TRPV1F2F12PLAUKDM4E | |
| SCHEMBL29744073 | 0.93 | F2 (0.58) | TRPV1F2F12PLAURAB9A | |
| SCHEMBL20641503 | 0.93 | F2 (0.58) | TRPV1F2F12PLAURAB9A | |
| SCHEMBL29743805 | 0.87 | CYP2A6 (0.55) | KDM4EHTTRAB9AKMT2AKCNK3 | |
| SCHEMBL23406076 | 0.87 | CYP2A6 (0.55) | KDM4EHTTRAB9AKMT2AKCNK3 | |
| SCHEMBL23406009 | 0.86 | GRM1 (0.57) | TRPV1F2F12PLAUHTT | |
| SCHEMBL23405923 | 0.86 | ADORA3 (0.57) | TRPV1KDM4ERAB9AKMT2A | |
| SCHEMBL29743831 | 0.86 | ADORA3 (0.57) | TRPV1KDM4ERAB9AKMT2A | |
| SCHEMBL29744058 | 0.86 | GRM1 (0.57) | TRPV1F2F12PLAUHTT | |
| SCHEMBL23405893 | 0.84 | RAB9A (0.67) | TRPV1KDM4ERAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377436-B2 | EAAT2 enhancing molecules | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377436-B2 | EAAT2 enhancing molecules | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | SLC1A2, SLC1A1, SLC1A3 | TRPV1 435/4885F2 4851/4885F12 4876/4885 |
| US-11377436-B2 | EAAT2 enhancing molecules | SLC1A2, SLC1A1, SLC1A3 | TRPV1 435/4885F2 4851/4885F12 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.